Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor [5]

Journal of Dermatology

Volumn 30, Issue 3, 2003, Pages 261-262

  Nakano, Junji ^a   Nakamura, Mitsutaka ^a  

^a Tokuyama Central Hospital   (Japan)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor; Gefitinib; Paronychia

Indexed keywords

ANTIBIOTIC AGENT; DIFLUPREDNATE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETRETINATE; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; CASE REPORT; FEMALE; GRANULATION TISSUE; HISTOPATHOLOGY; HUMAN; LETTER; LUNG CANCER; MONOTHERAPY; PARONYCHIA;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PARONYCHIA; QUINAZOLINES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 0037359382     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2003.tb00387.x     Document Type: Letter

References (3)

1. Hodak E, David M, Feuerman EJ: Excess granulation tissue during etretinate therapy, J Am Acad Dermatol, 6:1166-1167, 1984.
2. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, Br J Dermatol, 144:1169-1176, 2001.
3. Boucher KW, Davidson K, Mirakhur B, Goldberg J, Heymann WR: Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody, J Am Acad Dermatol, 45: 632-633, 2002.